LSP BioVentures
LSP BioVentures, operating as EQT Life Sciences, is a European venture capital firm managing approximately 3.5 billion EUR across 12 life sciences funds, investing 10-60M EUR per company in therapeutics, MedTech, diagnostics, and healthtech companies globally.
- Company typePrivate
- Founded2001
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What LSP BioVentures does
LSP BioVentures, operating commercially as EQT Life Sciences, is a European venture capital and growth-equity firm dedicated exclusively to the life sciences sector. Founded in 2001 as Life Sciences Partners (LSP) and rebranded under EQT Group in 2024, the firm manages approximately 3.5 billion EUR across 12 private funds organized around three strategies: Life Sciences Funds (LSP 1-7) for biotech drug development at all stages, Health Economic Funds for later-stage MedTech, digital health and diagnostics, and a specialized Dementia Fund for neurodegenerative disease. The firm invests 10-60M EUR per company and has backed over 150 private companies across therapeutics, medical devices, diagnostics and healthtech, with a current active portfolio of 65+ companies and 30+ investment professionals drawn from medical, scientific and industry backgrounds.
Revenue is generated through traditional fund-management economics: management fees on committed and invested capital across the 12 funds, supplemented by carried interest on successful exits such as Neuravi (acquired by Johnson & Johnson in 2017) and Amolyt Pharma (exited in 2024 at a 1bn+ valuation). Distribution of fund offerings occurs through qualified institutional investor LP channels, supported by a secure LP portal and direct outreach to entrepreneurs. Marketing and deal-sourcing channels include the annual BioCapital Europe conference, the THINQ content platform, a weekly newsletter, and direct referral/affiliate pathways.
Strategically, the firm is harvesting an active exit cycle (Tubulis to Gilead for up to USD 5.0 billion announced April 2026, Vivasure Medical to Haemonetics in January 2026) while extending its platform into radiopharmaceutical supply via a 2024 minority stake in PanTera alongside IBA and SCK CEN. Geographic reach spans Europe (Netherlands, Belgium, France, Ireland) and North America, with investments sourced globally. As part of EQT Group's Private Capital division, EQT Life Sciences operates with the institutional backing of one of Europe's largest alternative asset managers.
LSP BioVentures firmographics
Firmographics- Name
- LSP BioVentures
- Legal name
- EQT Life Sciences (operating as Life Sciences Partners / LSP)
- Website
- https://lspvc.com
- Company type
- Private
- Founded year
- 2001
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- LSP BioVentures, operating as EQT Life Sciences, is a European venture capital firm managing approximately 3.5 billion EUR across 12 life sciences funds, investing 10-60M EUR per company in therapeutics, MedTech, diagnostics, and healthtech companies globally.
- Ownership category
- akta.pro rank
Where LSP BioVentures is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
LSP BioVentures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Fund Management: EQT Life Sciences generates revenue through management fees and carried interest from its 12 private funds across three investment strategies (Life Sciences Funds LSP 1-7, Health Economic Funds, and Dementia Fund). Capital raised across funds totals approximately 3.5 billion EUR.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels8 records
LSP BioVentures product offering
Product offeringCore offering
LSP BioVentures, operating as EQT Life Sciences, is a venture capital/private equity firm that invests in innovative life sciences companies developing therapeutics, medical devices, diagnostics, and healthtech. The firm deploys 10-60M EUR per company across three strategies — Life Sciences Funds (LSP 1-7), Health Economic Funds, and a Dementia Fund — while providing strategic, clinical, operational, financial, and commercial guidance to portfolio companies. It has raised approximately 3.5 billion EUR across 12 private funds and invested in over 150 companies globally over a 30-year track record.
Product overview
EQT Life Sciences (formerly LSP BioVentures/Life Sciences Partners) is one of Europe's largest life sciences investors offering a family of specialized investment funds. The firm operates three core investment strategies: Life Sciences Funds (LSP 1-7) focused on biotech and drug development at all stages, Health Economic Funds targeting later-stage MedTech, Digital Health and Diagnostics companies, and a specialized Dementia Fund for neurodegenerative disease investments. The fund family collectively spans over 30 years of history with approximately 3.5 billion euros raised across 12 private funds. Investment advisory services include capital deployment as well as strategic, clinical, operational, financial, and commercial guidance for portfolio companies.
Differentiator
Problem solved
Functional benefit
Brands
- LSP 1-7 (Life Sciences Funds): Biotech funds focused on drug development at all stages.
- Health Economic Funds (LSP HEF 1-2, EQT HE 3)
- Dementia Fund (LSP Dementia)
Products and services
- Life Sciences Funds (LSP 1-7) Biotech investment funds focused on drug development at all stages, deploying capital of 10-60M EUR per company into innovative therapeutics developers globally. For institutional limited partners and life sciences entrepreneurs.
- Health Economic Funds (LSP HEF 1-2 / EQT HE 3)
- Dementia Fund
Quantifiable outcome
- Neuravi acquired by Johnson & Johnson in 2017, just two years after initial investment
- +1 more outcomes
Companies that use LSP BioVentures
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
LSP BioVentures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
LSP BioVentures partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Ion Beam Applications (IBA)coreIBA is a Belgian company and co-founder of PanTera, the joint venture producing Ac-225 radioisotope for cancer treatment. IBA and SCK CEN established PanTera in 2022, with EQT Life Sciences joining as an investor in 2024.
- SCK CEN (Belgian Nuclear Research Centre)coreSCK CEN is the Belgian Nuclear Research Centre and co-founder of PanTera, the joint venture producing Ac-225 radioisotope for cancer treatment. SCK CEN brings nuclear research expertise to the partnership.
Scale indicators6 records
Recent moves7 records
Expansion highlights5 records
LSP BioVentures competitors and assessment
Company assessmentDirect peers
- Versant Ventures: Versant Ventures is a healthcare-focused venture capital firm with operations in the US, Canada, and Europe. Comparable to EQT Life Sciences given transatlantic life sciences focus, multiple specialized strategies, and similar AUM scale.
- ARCH Venture Partners: ARCH Venture Partners is a US-based venture firm focused on founding and building biotech companies. Comparable as a long-tenured life sciences specialist with large fund vintages, though US-focused rather than European.
- Novo Holdings (Novo Ventures): Novo Ventures is the venture investment arm of Novo Holdings, a major global life sciences investor. Directly comparable as a long-duration life sciences investor with multi-billion AUM and focus on therapeutics development, with even larger scale than EQT Life Sciences.
- Sofinnova Partners: Sofinnova is a Paris-headquartered European life sciences VC with multiple specialized strategies including Crossover, Industrial Biotech, and MedTech. Highly comparable as a fellow European specialist life sciences investor with similar AUM scale and stage focus.
- Abingworth: Abingworth is a transatlantic life sciences investment firm with venture and clinical co-development strategies. Comparable to EQT Life Sciences given its specialized focus on therapeutics and medical devices with similar fund sizes and stage flexibility.
- Forbion: Forbion is a leading European life sciences venture capital firm managing multiple funds focused on biotech and MedTech investments. Directly comparable to EQT Life Sciences given similar European footprint, fund sizes in the hundreds of millions of euros, and focus on therapeutics and medical device companies.
- Atlas Venture: Atlas Venture is an early-stage life sciences VC firm focused on building biotech companies from inception. Comparable to EQT Life Sciences' LSP funds in stage focus and therapeutic orientation, though typically earlier-stage.
- Kurma Partners: Kurma Partners is a Paris-based European healthcare and life sciences VC firm. Directly comparable as a European specialist life sciences investor with similar stage focus on therapeutics and MedTech.
Broad incumbents
- OrbiMed Advisors: OrbiMed is a global healthcare-dedicated investment firm with public and private strategies across stages. Comparable as a large life sciences investor with multi-strategy approach, though significantly larger AUM and US-headquartered.
- GIMV: GIMV is a Belgian-listed private equity and venture capital firm with a meaningful health and care investment vertical. Comparable as a European PE firm with healthcare focus, though broader than EQT Life Sciences' pure-play life sciences strategy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
LSP BioVentures social profiles
Digital presenceLSP BioVentures financial estimates
Financial estimateRevenue estimate
Valuation estimate
LSP BioVentures leadership team
Management profileNumber of profiles
Profiles4 records
LSP BioVentures subsidiaries and ownership
Company hierarchySubsidiaries1 record
LSP BioVentures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
LSP BioVentures M&A and investment
M&A and investmentM&A
Investments29 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about LSP BioVentures
What does LSP BioVentures do?
LSP BioVentures, operating as EQT Life Sciences, is a venture capital/private equity firm that invests in innovative life sciences companies developing therapeutics, medical devices, diagnostics, and healthtech. The firm deploys 10-60M EUR per company across three strategies — Life Sciences Funds (LSP 1-7), Health Economic Funds, and a Dementia Fund — while providing strategic, clinical, operational, financial, and commercial guidance to portfolio companies. It has raised approximately 3.5 billion EUR across 12 private funds and invested in over 150 companies globally over a 30-year track record.
Is LSP BioVentures a public or private company?
LSP BioVentures is a private company. It is classified as corporate owned and is currently operating.
When was LSP BioVentures founded?
LSP BioVentures was founded in 2001. It employs 11 to 50 people.
Where is LSP BioVentures based?
LSP BioVentures is headquartered in Cambridge, United States, in the North America region.
How does LSP BioVentures make money?
One revenue line is on record: fund Management.
Who are LSP BioVentures's main competitors?
Direct peers on record are Versant Ventures, ARCH Venture Partners, Novo Holdings (Novo Ventures), Sofinnova Partners, Abingworth, Forbion, Atlas Venture and Kurma Partners. Broad incumbents are OrbiMed Advisors and GIMV.
Does LSP BioVentures have an API?
No public API is recorded for LSP BioVentures.